Foghorn Therapeutics Analyst Ratings
Foghorn Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Stryker (SYK), Foghorn Therapeutics (FHTX)
Foghorn Therapeutics: Buy Rating Affirmed Amidst Promising Pipeline and Strategic Alliances
Foghorn Therapeutics Analyst Ratings
Foghorn Therapeutics Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Foghorn Therapeutics (FHTX), Sensus Healthcare (SRTS)
Morgan Stanley Maintains Equal-Weight on Foghorn Therapeutics, Lowers Price Target to $6
Foghorn Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX), Aurinia Pharmaceuticals (AUPH) and Biogen (BIIB)
Foghorn Therapeutics Analyst Ratings
Morgan Stanley Sticks to Its Hold Rating for Foghorn Therapeutics (FHTX)
Bank of America Securities Keeps Their Buy Rating on Foghorn Therapeutics (FHTX)
Goldman Sachs Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $19
Analyst Ratings for Foghorn Therapeutics
Wedbush Trims Foghorn Therapeutics Price Target to $13 From $14, Maintains Outperform Rating
Foghorn Therapeutics (FHTX) Gets a Buy From H.C. Wainwright
What 6 Analyst Ratings Have To Say About Foghorn Therapeutics
HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $20 Price Target
Analysts' Opinions Are Mixed on These Healthcare Stocks: Option Care Health (OPCH), UnitedHealth (UNH) and Foghorn Therapeutics (FHTX)
No Data